A study measures the long-term downside of prostate cancer screening A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Small molecule inhibitor blocks prostate cancer bone metastasis

Findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine, published in Pharmacological Research, show that a targeted small molecule inhibitor, IVMT-Rx-4, may prevent prostate tumors from spreading to an advanced and incurable stage in the bones.

April 03, 2026

Vol.52 No.13

Clinical Roundup

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Researchers “turbocharge” immune cells to attack prostate cancer

A team of researchers engineered a new class of “turbocharged” T cells that may be stronger, longer-lasting, and more precise at killing prostate cancer cells. The approach represents a step toward developing safer, more effective T-cell therapies for prostate cancer and could potentially be adapted to treat a wide range of other tumors.

March 27, 2026

Vol.52 No.12

In Brief

KU Cancer Center deploys new mobile cancer screening bus

The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially for those with very low PSA levels before treatment.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

A study measures the long-term downside of prostate cancer screening

A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

YOU MAY BE INTERESTED IN

Small molecule inhibitor blocks prostate cancer bone metastasis

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Researchers “turbocharge” immune cells to attack prostate cancer

KU Cancer Center deploys new mobile cancer screening bus

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login